Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25698
Submission : 2011-12-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22163
Submission : 2008-10-27
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Lead Product(s): Erythropoietin EPO
Therapeutic Area: Hematology Brand Name: rHuEPO
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Blau Farmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 25, 2022
Lead Product(s) : Erythropoietin EPO
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Blau Farmaceutica
Deal Size : Undisclosed
Deal Type : Partnership
Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Details : The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Brand Name : rHuEPO
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Finished Drug Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 598
2019 Revenue in Millions : 867
Growth (%) : -31
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 270
2018 Revenue in Millions : 297
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 552
2019 Revenue in Millions : 790
Growth (%) : -30
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 521
2020 Revenue in Millions : 598
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 266
2019 Revenue in Millions : 292
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 479
2020 Revenue in Millions : 552
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 506
2021 Revenue in Millions : 521
Growth (%) : -3
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 2,031
2014 Revenue in Millions : 1,856
Growth (%) : -9%
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2014 Revenue in Millions : -9.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 1,096
2016 Revenue in Millions : 1,282
Growth (%) : -15
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
